Solid neoplasms can elicit both antiand pro-tumor immune responses, and such conflicting activities can often be detected within individual lesions. 1, 2 Most past studies dealing with antitumor immunity have focused on CD8 + cytotoxic T cells, as their cytotoxic activity was deemed critical for tumor eradication. Recent work indicates that specific subsets of CD4 + T cells (namely, T H 1 cells), B cells, macrophages as well as dendritic cells provide an important contribution to antitumor immune responses as they secrete immunostimulatory factors or mediate antigen-presenting functions. Conversely, immunosuppressive cells including regulatory T cells, myeloid-derived suppressor cells and M2 macrophages have been ascribed with an important role for oncogenesis and tumor progression. While the balance between anti-and pro-tumor immune responses may dictate the elimination of malignant T cells during the early stages of tumorigenesis, the quantity of infiltrating lymphocytes (TILs) at surgery has been shown to predict disease outcome in patients affected by various solid neoplasms. 3 Thus, while antitumor immune responses generally fail to control the growth of primary tumors, cancer patients developing such responses to their neoplastic lesions have a better prognosis than patients that fail to do so. Indeed, at least theoretically, TILs might generate memory cells that mediate anticancer immunosurveillance upon tumor resection.
The key factors for the development and propagation of tumor-specific immunological memory remain unknown, although some clues are now emerging from studies of human malignancies. The peritumoral infiltrate of human lesions principally contains CD4 + and CD8 + T cells, sometimes in association with B cells. By studying human breast carcinoma (BC), we have recently discovered an important association between the presence of tumor-infiltrating CD4 + follicular helper T (T FH ) cells, which localize to peritumoral tertiary lymphoid structures (TLS), and patient survival. 4 Our study aimed at producing a representative portrait of CD4 + cells that home to B cell follicles in secondary lymphoid organs (SLOs). Since then, these specialized helper T cells have been extensively characterized in murine models, revealing that they are both required and limiting for the formation of germinal centers (GCs). 5 Together with follicular dendritic cells, T FH cells also regulate the selection of somatically mutated antigen-specific 6 Our study on BC-infiltrating CD4 + lymphocytes is the first to describe intratumoral T FH cells in a non-hematological cancer and to show that their presence has a positive prognostic value (Fig. 1) .
The significance of our observations might not be immediately apparent because humoral immunity has long been considered as the poor cousin in antitumor immunity. 7 Nonetheless, a recent study has clearly established a link between the presence of antigen-experienced tumor-infiltrating B cells and survival in ovarian cancer patients. 8 + T cells in extensively-infiltrated BCs are principally housed in TLS and hence exhibit an improved activation profile. We provided experimental support for this concept by treating CD4 + T cells from healthy individuals with supernatants from primary tumor cell cultures, largely recapitulating the profiles observed in vivo. Of note, these supernatants exhibited robust immunosuppressive effects on activated (as opposed to non-activated) CD4 + T cells, with supernatants from minimally infiltrated tumors being the most efficient in this respect. Taken together, these observations suggest that lymphocytes housed in peritumoral TLS are activated in response to local antigens within a protected microenvironment. Once they leave the TLS and invade the immunosuppressive tumor bed, these cells may quickly undergo anergy but perhaps this is less relevant from a clinical perspective than their ability to retain immunological memory. Ectopic or tertiary lymphoid structures that are structurally similar to SLOs not only have been identified at sites of autoimmune reactions in patients with rheumatoid arthritis or Sjögren's syndrome, but also have been associated with chronic inflammation in patients undergoing allograft rejection. 10 These TLS are thought to indicate a local chronic inflammatory response to persistent antigenic stimulation, and to mediate pathogenic effects through the aberrant secretion of immunoglobulins. TLS organization in BC lesions also mimic the architecture of a SLO, including a T cell zone and a B cell follicle that contains an active GC. The presence of T FH cells/TLS in BC lesions (as detected by a genetic signature including 8 components) is indicative of good clinical outcomes, both for long-term survival in untreated BC patients or pathological complete responses in BC patients receiving neo-adjuvant chemotherapy. Although TLS may initially form adjacent to the tumor bed in the context of a chronic inflammatory response to malignancy (which generally favors disease progression), they may provide considerable benefits by sustaining the development of tumor-specific effector and memory lymphocytes.
